Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and benefits of SG1002, including
overcoming deficits in circulating hydrogen sulfide and nitrite found in heart failure
patients, with secondary endpoints focused on improving clinical endpoints.